

# Genito-Urinary Drug Industry Players Invest In Development Of New Class Drugs

*The Business Research Company's Genito-Urinary Drugs Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026*


LONDON, GREATER LONDON, UK, January 27, 2022 /EINPresswire.com/ -- Genito-urinary drugs market insights include pharmaceutical companies investing in development of new class drugs for treating overactive bladders (OAB). Earlier anti-muscarinic agents have been used for the treatment of

OAB. Going forward, the market is expected to be driven by a new class of drug known as beta-3 adrenergic agonists that has been increasingly used to treat OAB. Beta-3 adrenergic agonists are drugs which cause the bladder muscles to relax without causing side effects such as dry mouth. For instance, In GEMTESA's new drug application (NDA) was submitted to the US Food and Drug Administration (FDA), and it was accepted for review in March 2020. GEMTESA® is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency.

The main types of genito-urinary drugs are hormonal contraceptives, drugs for benign prostatic hypertrophy, drugs for infertility, drugs for erectile dysfunction, drugs for urinary incontinence and overactive bladder, drugs for infections and others, drugs for hormonal replacement therapy and diuretics. Hormonal contraceptives are medications or devices that reduce the likelihood of becoming pregnant. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others.

Read More On The Global Genito-Urinary Drug Market Report:

<https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report>



The global genito-urinary drugs market size is expected to grow from \$40.40 billion in 2021 to \$42.75 billion in 2022 at a compound annual growth rate (CAGR) of 5.8%. Genito-urinary drugs market growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach \$63.83 billion in 2026 at a CAGR of 10.5%.

The aging population profile of most countries contributed to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period.

Major players covered in the global genito-urinary drug industry are Sanofi S.A, GlaxosmithKline, AstraZeneca, AbbVie, Reckitt, Benckiser Group plc, Astellas Pharma Inc., Otsuka Holdings Co Ltd, Pfizer Inc., Merck KGaA and Daiichi Sankyo Company.

[TBRC's global genito-urinary drugs industry analysis](#) report is segmented by type into hormonal contraceptives, drugs for benign prostatic hypertrophy, drugs for infertility, drugs for erectile dysfunction, drugs for urinary incontinence and overactive bladder, drugs for infections and others, drugs for hormonal replacement therapy, diuretics, by distribution channel into hospital pharmacies, retail pharmacies/ drug stores, others, by route of administration into oral, parenteral, others, by drug classification into branded drugs, generic drugs, by mode of purchase into prescription-based drugs, over-the-counter drugs.

[Genito-Urinary Drugs Global Market Report 2022](#) – By Type (Hormonal Contraceptives, Drugs For Benign Prostatic hypertrophy, Drugs For Infertility, Drugs For Erectile Dysfunction, Drugs For Urinary Incontinence And Overactive Bladder, Drugs For Infections And Others, Drugs For Hormonal Replacement Therapy, Diuretics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a genito-urinary drug market overview, forecast genito-urinary drug market size and growth for the whole market, genito-urinary drug market segments, geographies, genito-urinary drug market trends, genito-urinary drug market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request For A Sample Of The Global Genito-Urinary Drug Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=3144&type=smp>

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment Global Market Report 2021 - By Type (Urinary Incontinence Devices, Pelvic Organ Prolapse Devices), By Urinary Incontinence Devices (Artificial Urinary Sphincters, Electrical Stimulation Devices, Urethral Slings, Catheters), By Pelvic Organ Prolapse Devices (Vaginal Mesh, Vaginal Pessary), By Incontinence Type (Stress Incontinence, Urge Incontinence, Overflow Incontinence, Functional Incontinence), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Use), COVID-19 Impact And Recovery

<https://www.thebusinessresearchcompany.com/report/urinary-incontinence-and-pelvic-organ-prolapse-devices-and-equipment-global-market-report>

Bladder Cancer Drugs Global Market Report 2021 - By Type (Non-Muscle-Invasive Bladder Cancer, Muscle-Invasive Bladder Cancer), By Application (Low-Grade Tumors, High-Grade Tumors), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), COVID-19 Impact And Recovery

<https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report>

Drugs For Benign Prostatic Hypertrophy Global Market Report 2021 - By Type (Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor), By End User (Hospital Pharmacies, Retail Pharmacies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), COVID-19 Impact And Recovery

<https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report>

Know More About [The Business Research Company?](https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx)

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [info@tbrc.info](mailto:info@tbrc.info)

Check out our:

LinkedIn: <https://bit.ly/3b7850r>

Twitter: <https://bit.ly/3b1rmjS>

YouTube: [https://www.youtube.com/channel/UC24\\_fl0rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_fl0rV8cR5DxICpgmyFQ)

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/561641346>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.